Tilray Q3 FY2026: International Cannabis Up 41% YoY

Tilray Brands (NASDAQ: TLRY) entered May 2026 with a story increasingly defined by what is happening outside North America. The company's most recent fiscal disclosures show international cannabis revenue up 41% year-over-year through the first nine months of fiscal 2026 — reaching $57.7 million — while the broader US multi-state operator (MSO) cohort posted a coordinated rally on news flow around federal rescheduling. The combined picture is a sector that, for the first time in years, has a credible bull case that does not depend entirely on a single regulatory event.

The Headline Numbers

Tilray reported fiscal first-quarter 2026 net revenue of $200 million, up 5% year-over-year, with cannabis revenue growing 5% and alcoholic-beverage sales down less than 1%. Adjusted EBITDA margin expanded roughly 20 basis points to 4.9%, modest improvement but in the right direction. The more striking number sits inside the segment detail: international cannabis revenue grew 41% year-over-year for the first nine months of fiscal 2026 to $57.7 million, fueled by higher volumes in Tilray's German, Polish and Australian medical channels.

Tilray's Q3 FY2026 release showed mixed results — revenue beat estimates while adjusted earnings missed — but the international segment's growth profile is now the cleanest narrative the company has produced since its 2021 merger with Aphria. High Tide's German subsidiary, Remexian Pharma GmbH, separately reported 7.6 tonnes of medical cannabis distributed in Germany for its quarter ended April 30, 2026 — its highest quarterly volume ever — confirming that German medical demand following last year's policy reforms is real and durable.

The MSO Tape: Cohort Rally, Not Single-Name Pop

Tilray's results landed during a broader rerating of the US cannabis tape. As of early May 2026, the US MSO basket averaged a +3.32% session, the cannabis ETF complex closed up +3.33%, and Innovative Industrial Properties led with +14.03% on the day. Cresco Labs (+7.26%), Curaleaf (+6.75%) and Trulieve (+5.67%) all printed multi-percent gains, signaling that the bid was cohort-wide rather than name-specific.

The AdvisorShares Pure US Cannabis ETF (MSOS) traded near $5.11 against a 52-week range of $2.06–$7.25. Its five largest positions — Trulieve, Green Thumb Industries, Cresco Labs, Verano Holdings and Curaleaf — make up roughly 61% of the fund's total assets, so any sustained recovery in those names lifts the entire complex.

Why Rescheduling Changes the Math

The Justice Department's move to place FDA-approved cannabis products and state-licensed medical cannabis providers under Schedule III is the most consequential structural change US operators have seen. The mechanical effect is concentrated in two places. First, IRS Code Section 280E — which currently denies cannabis businesses ordinary federal tax deductions, pushing effective rates into the 60-70% range — would no longer apply to Schedule III activity, dropping effective rates toward the standard 21% corporate rate. Second, banking and capital-markets access broadens as the federal-controlled-substance overhang lessens.

ATB Capital Markets has forecast roughly 4% MSO revenue growth in 2026, with mergers and acquisitions providing a potential second-half boost. The combination — tax relief, better banking, modest organic growth and an active M&A environment — is what is driving the cohort rally.

Tilray's Specific Story: A Global Operator in a US-Driven Tape

Tilray is unusual among large cannabis-adjacent equities because its narrative is no longer primarily a US-rescheduling trade. The company has built genuine commercial scale in Germany (medical), Poland (medical), Australia (medical) and Portugal (cultivation), alongside its Canadian recreational footprint and its US-based alcohol business under SweetWater, Montauk, Breckenridge Distillery and others. The 41% international cannabis growth print is the closest thing the company has produced to a structural tailwind it controls.

The Tilray-Carlsberg licensing deal announced earlier in 2026 — under which Carlsberg will produce and distribute several Tilray cannabis-beverage brands across European markets — adds a second international vector. The deal is small relative to Carlsberg's overall scale but meaningful for Tilray: it converts a capital-intensive infrastructure project into a royalty-style revenue stream and embeds Tilray brands inside one of Europe's largest beverage-distribution networks.

The Bear Case Still Has Legs

The bull thesis is not unanimous. California's retail market continues to soften under oversupply and persistent price compression. Federal rescheduling does not legalize interstate cannabis commerce, so US MSOs still cannot ship across state lines — limiting the operating leverage that any other consumer-staples industry would capture from a national footprint. And many of these companies still carry meaningful debt loads originated when capital was cheaper.

For Tilray specifically, the alcoholic-beverage segment continues to deliver only modest growth, and the Canadian recreational market remains structurally low-margin. Bulls argue that international cannabis is now the swing factor; bears note that international medical markets are still small relative to Tilray's overall revenue base.

Implications for Investors and Operators

For investors, May 2026 looks like the first quarter in years where both a top-down catalyst (rescheduling) and bottom-up fundamentals (international growth, MSO revenue inflection) are pointing the same direction. That does not eliminate execution risk — most cannabis companies still trade well below their 2021 highs for reasons beyond regulation — but it broadens the field of names that have a credible operating story.

For operators, Tilray's international print reinforces a strategic question the sector has been ducking: as the US opens incrementally, does it still make sense to allocate capital to European, Australian and Latin American medical channels that have clearer regulatory paths? The Q3 FY2026 numbers suggest yes.

Key Takeaways

• Tilray's international cannabis revenue grew 41% year-over-year through the first nine months of fiscal 2026 to $57.7 million.
• Q3 FY2026 results were mixed (revenue beat, earnings missed), but international growth is now the clearest standalone narrative.
• US MSOs rallied alongside on rescheduling momentum, with the MSOS ETF up over 3% in early May 2026 and IIPR leading with +14%.
• Schedule III treatment would remove 280E and lower effective tax rates from 60-70% toward the standard 21%.
• Bear case: California oversupply, no interstate commerce yet, and lingering debt loads still cap multiples.

Explore cannabis news, find dispensaries, and join the community at Budpedia.

Not investment advice. Cannabis equities remain volatile and federal regulatory outcomes are uncertain. Consult a licensed financial advisor.

Find verified shops in your state through Budpedia's cannabis dispensary directory.